ESG206 / Escugen Biotechnology - LARVOL DELTA

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | N=12 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • First-in-human • Trial withdrawal • Hematological Malignancies • Oncology

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | N=10 ➔ 13 | Trial completion date: Dec 2025 ➔ Jan 2025 | Trial primary completion date: Aug 2025 ➔ Jan 2025 | Recruiting ➔ Completed

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Nov 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

A Phase 1/2 Study of ESG206 in Patients with Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1/2 | N=84 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd

New P1/2 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Trial completion date: May 2025 ➔ Dec 2026 | Trial primary completion date: Jan 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

Preliminary results of a first-in-human study on ESG206, a novel anti-BAFF-R monoclonal antibody, in relapsed or refractory B-cell malignancies. (ASCO 2024) - P1 | "Preclinical investigations have successfully validated the antitumor effects of ESG206 across a spectrum of malignant B cell disease models, including lymphoma xenografts which were resistant to Rituximab, and Ibrutinib. Preliminary data indicates ESG206 is well-tolerated with promising efficacy signals in R/R B-cell malignancies. These encouraging results warrant continued clinical evaluation as the Phase I study progresses. Clinical trial information: NCT05263739."

P1 data • Anemia • Diffuse Large B Cell Lymphoma • Dyslipidemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • Solid Tumor

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Oncology

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd

New P1 trial • Hematological Malignancies • Oncology

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Trial completion date: May 2024 ➔ May 2025 | Trial primary completion date: Jan 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Initiation date: May 2022 ➔ Sep 2022

Trial initiation date • Hematological Malignancies • Oncology